{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:13:58Z","timestamp":1792826038212,"version":"4.5.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0209264","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T18:59:22Z","timestamp":1548356362000},"page":"e0209264","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["Nimesulide-induced hepatotoxicity: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"14","author":[{"given":"Jeongyoon","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4487-4450","authenticated-orcid":true,"given":"Euni","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"issue":"9149","key":"ref1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(98)12154-2","article-title":"COX-2 inhibitors","volume":"353","author":"CJ Hawkey","year":"1999","journal-title":"The Lancet"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0022-3859.40786","article-title":"Nimesulide-induced hepatitis and toxic epidermal necrolysis","volume":"54","author":"S Chatterjee","year":"2008","journal-title":"Journal of postgraduate medicine"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1185\/03007995.2015.1100986","article-title":"Acute pain: a multifaceted challenge\u2014the role of nimesulide","volume":"32","author":"HG Kress","year":"2016","journal-title":"Current medical research and opinion"},{"issue":"suppl_1","key":"ref4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/rheumatology\/38.suppl_1.33","article-title":"Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide","volume":"38","author":"W. Wober","year":"1999","journal-title":"Rheumatology (Oxford, England)"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1517\/14656566.2.11.1859","article-title":"COX-2 inhibitors compared and contrasted","volume":"2","author":"A Bennett","year":"2001","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"ref6","first-page":"483A","article-title":"Nimesulide hepatotoxicity: Evidence from six cases","volume":"26","author":"F Bessone","year":"1997","journal-title":"Hepatology"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/dmd.116.074104","article-title":"Nimesulide and 4'-Hydroxynimesulide as Bile Acid Transporters Inhibitors Are Contributory Factors for Drug-Induced Cholestasis","volume":"45","author":"L Zhou","year":"2017","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"issue":"7405","key":"ref8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/bmj.327.7405.18","article-title":"Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs","volume":"327","author":"G Traversa","year":"2003","journal-title":"British Medical Journal"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/bcp.12938","article-title":"Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy","volume":"82","author":"M Donati","year":"2016","journal-title":"British journal of clinical pharmacology"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40264-012-0013-7","article-title":"Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study","volume":"36","author":"SE Gulmez","year":"2013","journal-title":"Drug safety"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/pds.1966","article-title":"Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs","volume":"19","author":"CH Lee","year":"2010","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1365-2036.2007.03338.x","article-title":"Risk of acute liver injury associated with the use of drugs: a multicentre population survey","volume":"25","author":"M Sabate","year":"2007","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"ref13","unstructured":"EMEA. Committee for Proprietary Medicinal Products (CPMP) opinion following an article 31 referral: European Agency for the Evaluation of Medicinal Products; [updated 2004 May 7]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Nimesulide_31\/WC500013818.pdf<\/ext-link>."},{"key":"ref14","unstructured":"IMB. IMB Suspension of Marketing of Nimesulide containing medicines: Irish Medicines Board; [updated 2007 July 1 ]. Available from: http:\/\/www.hpra.ie\/docs\/default-source\/Safety-Notices\/human-medicines\u20143rd-party-publications\u2014hpra-suspension-of-marketing-of-nimesulide-containing-medicines-document.pdf?sfvrsn=0<\/ext-link>."},{"key":"ref15","unstructured":"EMA. Assessment report for Nimesulide containing medicinal products for systemic use: European Medicines Agency; [updated 2012 Apr 19]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Nimesulide_31\/WC500125574.pdf<\/ext-link>."},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"62","author":"D Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"key":"ref17","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses","author":"G Wells","year":"2014"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in Drug and Herb Induced Liver Injury: The Update","volume":"17","author":"G Danan","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","article-title":"Use of measures of disproportionality in pharmacovigilance","volume":"25","author":"AC Egberts","year":"2002","journal-title":"Drug safety"},{"key":"ref20","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions The Cochrane Collaboration; 2011. Available from: www.handbook.cochrane.org<\/ext-link>."},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/pds.1665","article-title":"Nimesulide associated fulminant hepatic failure","volume":"17","author":"SL Walker","year":"2008","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s002280100312","article-title":"Fatal hepatotoxicity secondary to nimesulide","volume":"57","author":"G Merlani","year":"2001","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1472-8206.2011.00991.x","article-title":"Adverse drug reactions associated with the use of NSAIDs: a case\/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002\u20132006","volume":"27","author":"M Lapeyre\u2010Mestre","year":"2013","journal-title":"Fundamental & clinical pharmacology"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1472-8206.2006.00416.x","article-title":"Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: Analysis from national spontaneous reporting systems","volume":"20","author":"M Lapeyre-Mestre","year":"2006","journal-title":"Fundamental and Clinical Pharmacology"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.dld.2009.06.009","article-title":"Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication","volume":"42","author":"A Licata","year":"2010","journal-title":"Digestive and Liver Disease"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00228-006-0222-z","article-title":"Hepatic adverse drug reactions: a case\/non-case study in Italy","volume":"63","author":"D Motola","year":"2007","journal-title":"European journal of clinical pharmacology"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.clinthera.2006.08.014","article-title":"Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: A case\/noncase analysis of spontaneous reports","volume":"28","author":"D Sanchez-Matienzo","year":"2006","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2165\/11535340-000000000-00000","article-title":"Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase\u2122","volume":"33","author":"A Suzuki","year":"2010","journal-title":"Drug safety"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-8278(98)80188-8","article-title":"Nimesulide-induced acute hepatitis: Evidence from six cases","volume":"29","author":"W Van Steenbergen","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"4","key":"ref30","first-page":"359","article-title":"Nimesulide-induced acute hepatitis","volume":"16","author":"E Cholongitas","year":"2003","journal-title":"Annals of Gastroenterology"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/MEG.0b013e3282eeb4cc","article-title":"Liver transplantation for nonsteroidal anti-inflammatory drug-induced liver failure: nimesulide as the first implicated compound","volume":"19","author":"SN Dastis","year":"2007","journal-title":"European journal of gastroenterology & hepatology"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/00044011-200525060-00008","article-title":"Nimesulide-induced hepatotoxicity in a previously healthy woman","volume":"25","author":"L Gallelli","year":"2005","journal-title":"Clinical Drug Investigation"},{"issue":"1","key":"ref33","first-page":"114","article-title":"A case of nimesulide induced hepatitis","volume":"59","author":"Hee Bok Chae","year":"2000","journal-title":"Korean Journal of Internal Medicine"},{"issue":"9\u201310","key":"ref34","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2298\/SARH0910550L","article-title":"Cholestatic hepatitis associated with nimesulide\u2014a case report","volume":"137","author":"S Luki\u0107","year":"2009","journal-title":"Srpski arhiv za celokupno lekarstvo"},{"issue":"9","key":"ref35","first-page":"742","article-title":"Acute liver failure due to a treatment by nimesulide: Another case and review","volume":"27","author":"M Page","year":"2008","journal-title":"Annales Francaises d'Anesthesie et de Reanimation"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/003655202761020650","article-title":"Nimesulide-induced severe hemolytic anemia and acute liver failure leading to liver transplantation","volume":"37","author":"L Rodrigo","year":"2002","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"9","key":"ref37","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1177\/106002800103500901","article-title":"Nimesulide-induced acute hepatitis","volume":"35","author":"W Sbeit","year":"2001","journal-title":"Annals of Pharmacotherapy"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1365-2796.2000.00612.x","article-title":"Fatal hepatitis and renal failure during treatment with nimesulide","volume":"247","author":"A Schattner","year":"2000","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"ref39","first-page":"582","article-title":"Nimesulide-induced hepatotoxicity and fatal hepatic failure","volume":"48","author":"HH Tan","year":"2007","journal-title":"Singapore Medical Journal"},{"issue":"2","key":"ref40","first-page":"89","article-title":"Nimesulide-induced hepatitis and acute liver failure","volume":"1","author":"P Weiss","year":"1999","journal-title":"The Israel Medical Association journal: IMAJ"},{"issue":"2","key":"ref41","first-page":"153","article-title":"Effects of the European restrictive actions concerning nimesulide prescription: A simulation study on hepatopathies and gastrointestinal bleedings in Italy","volume":"46","author":"M Venegoni","year":"2010","journal-title":"Annali dell'Istituto Superiore di Sanita"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1590\/S0080-623420140000400023","article-title":"Causes for the underreporting of adverse drug events by health professionals: a systematic review","volume":"48","author":"FR Varallo","year":"2014","journal-title":"Revista da Escola de Enfermagem da USP"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/pds.1865","article-title":"Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins","volume":"19","author":"F van Hunsel","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2042098610386281","article-title":"Drug-induced liver injury in older adults","volume":"1","author":"SJ Mitchell","year":"2010","journal-title":"Therapeutic Advances in Drug Safety"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002018-200730040-00001","article-title":"Drug-induced liver injury","volume":"30","author":"G Abboud","year":"2007","journal-title":"Drug safety"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1472-8206.2004.00224.x","article-title":"Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care","volume":"18","author":"I Lacroix","year":"2004","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"ref47","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.22895","article-title":"Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex","volume":"49","author":"MI Lucena","year":"2009","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"ref48","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period","volume":"129","author":"RJ Andrade","year":"2005","journal-title":"Gastroenterology"},{"issue":"6","key":"ref49","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/14740338.6.6.673","article-title":"Idiosyncratic drug-induced liver injury: an overview","volume":"6","author":"SH Hussaini","year":"2007","journal-title":"Expert opinion on drug safety"},{"issue":"6","key":"ref50","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"JL Montastruc","year":"2011","journal-title":"British journal of clinical pharmacology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0209264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T04:02:30Z","timestamp":1588996950000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0209264"}},"subtitle":[],"editor":[{"given":"Yun-Wen","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0209264","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]}}}